{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:10:29Z","timestamp":1793801429001,"version":"4.6.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008091","name":"Golestan University of Medical Sciences","doi-asserted-by":"publisher","award":["110632"],"award-info":[{"award-number":["110632"]}],"id":[{"id":"10.13039\/501100008091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["96010101"],"award-info":[{"award-number":["96010101"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-022-02997-3","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T19:13:34Z","timestamp":1669144414000},"page":"841-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Suppression of CD56bright NK cells in breast cancer patients is associated with the PD-1 and TGF-\u03b2RII expression"],"prefix":"10.1007","volume":"25","author":[{"given":"Elaheh","family":"Arianfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Reza","family":"Khandoozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-9002","authenticated-orcid":false,"given":"Ali","family":"Memarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"issue":"1","key":"2997_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2997_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cdtm.2015.02.001","volume":"1","author":"YJ Xiang","year":"2015","unstructured":"Xiang YJ, Fu QY, Ma ZB, Gao DZ, Zhang Q, Li YY, et al. Screening for candidate genes related to breast cancer with cDNA microarray analysis. Chronic Dis Transl Med. 2015;1(2):65\u201372. https:\/\/doi.org\/10.1016\/j.cdtm.2015.02.001.","journal-title":"Chronic Dis Transl Med"},{"issue":"1","key":"2997_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12885-018-4441-3","volume":"18","author":"JP Bates","year":"2018","unstructured":"Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. BMC Cancer. 2018;18(1):556. https:\/\/doi.org\/10.1186\/s12885-018-4441-3.","journal-title":"BMC Cancer"},{"issue":"3","key":"2997_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/08830185.2020.1845670","volume":"40","author":"E Arianfar","year":"2021","unstructured":"Arianfar E, Shahgordi S, Memarian A. Natural killer cell defects in breast cancer: a key pathway for tumor evasion. Int Rev Immunol. 2021;40(3):197\u2013216. https:\/\/doi.org\/10.1080\/08830185.2020.1845670.","journal-title":"Int Rev Immunol"},{"key":"2997_CR5","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.3389\/fimmu.2019.03038","volume":"10","author":"O Melaiu","year":"2019","unstructured":"Melaiu O, Lucarini V, Cifaldi L, Fruci D. Influence of the tumor microenvironment on NK cell function in solid tumors. Front Immunol. 2019;10:3038. https:\/\/doi.org\/10.3389\/fimmu.2019.03038.","journal-title":"Front Immunol"},{"issue":"3","key":"2997_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V","volume":"88","author":"S Ishigami","year":"2000","unstructured":"Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88(3):577\u201383. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(20000201)88:3%3c577::AID-CNCR13%3e3.0.CO;2-V.","journal-title":"Cancer"},{"issue":"12","key":"2997_CR7","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1002\/(sici)1097-0142(19970615)79:12<2320::aid-cncr5>3.0.co;2-p","volume":"79","author":"S Coca","year":"1997","unstructured":"Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79(12):2320\u20138. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19970615)79:12%3c2320::aid-cncr5%3e3.0.co;2-p.","journal-title":"Cancer"},{"issue":"2","key":"2997_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.114","volume":"47","author":"SR Yoon","year":"2015","unstructured":"Yoon SR, Kim TD, Choi I. Understanding of molecular mechanisms in natural killer cell therapy. Exp Mol Med. 2015;47(2): e141. https:\/\/doi.org\/10.1038\/emm.2014.114.","journal-title":"Exp Mol Med"},{"issue":"4","key":"2997_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.bbmt.2011.11.023","volume":"18","author":"SA Dezell","year":"2012","unstructured":"Dezell SA, Ahn YO, Spanholtz J, Wang H, Weeres M, Jackson S, et al. Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin-and stromal cell-supported methods. Biol Blood Marrow Transplant. 2012;18(4):536\u201345. https:\/\/doi.org\/10.1016\/j.bbmt.2011.11.023.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2997_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1615\/CritRevImmunol.2016017387","volume":"36","author":"AY Mah","year":"2016","unstructured":"Mah AY, Cooper MA. Metabolic regulation of natural killer cell IFN-\u03b3 production. Crit Rev Immunol. 2016;36(2):131\u201347. https:\/\/doi.org\/10.1615\/CritRevImmunol.2016017387.","journal-title":"Crit Rev Immunol"},{"key":"2997_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00699","volume":"8","author":"Mathieu Amand","year":"2017","unstructured":"Amand M, Iserentant G, Poli A, Sleiman M, Fievez V, Sanchez IP, et al. Human CD56dimCD16dim cells as an individualized natural killer cell subset. Front Immunol. 2017;8:699. https:\/\/doi.org\/10.3389\/fimmu.2017.00699.","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"2997_CR12","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.4049\/jimmunol.1502570","volume":"196","author":"T Michel","year":"2016","unstructured":"Michel T, Poli A, Cuapio A, Briquemont B, Iserentant G, Ollert M, et al. Human CD56bright NK cells: an update. J Immunol. 2016;196(7):2923\u201331. https:\/\/doi.org\/10.4049\/jimmunol.1502570.","journal-title":"J Immunol"},{"key":"2997_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fimmu.2012.00299","volume":"3","author":"L Fern\u00e1ndez-Messina","year":"2012","unstructured":"Fern\u00e1ndez-Messina L, Reyburn HT, Val\u00e9s-G\u00f3mez M. Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol. 2012;3:299. https:\/\/doi.org\/10.3389\/fimmu.2012.00299.","journal-title":"Front Immunol"},{"issue":"4","key":"2997_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1365-2567.2007.02652.x","volume":"121","author":"AR Mistry","year":"2007","unstructured":"Mistry AR, O\u2019Callaghan CA. Regulation of ligands for the activating receptor NKG2D. Immunology. 2007;121(4):439\u201347. https:\/\/doi.org\/10.1111\/j.1365-2567.2007.02652.x.","journal-title":"Immunology"},{"issue":"10","key":"2997_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nri1199","volume":"3","author":"DH Raulet","year":"2003","unstructured":"Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3(10):781\u201390. https:\/\/doi.org\/10.1038\/nri1199.","journal-title":"Nat Rev Immunol"},{"issue":"56","key":"2997_CR16","doi-asserted-by":"publisher","first-page":"96384","DOI":"10.18632\/oncotarget.21466","volume":"8","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Chen N, Yu Y, Zhou L, Niu C, Liu Y, et al. Prognostic value of MICA\/B in cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(56):96384\u201395. https:\/\/doi.org\/10.18632\/oncotarget.21466.","journal-title":"Oncotarget"},{"issue":"3","key":"2997_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261\u20138. https:\/\/doi.org\/10.1038\/85330.","journal-title":"Nat Immunol"},{"key":"2997_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2997_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2017","unstructured":"Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139(1):335-46.e3. https:\/\/doi.org\/10.1016\/j.jaci.2016.04.025.","journal-title":"J Allergy Clin Immunol"},{"key":"2997_CR20","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3389\/fimmu.2019.01242","volume":"10","author":"S Pesce","year":"2019","unstructured":"Pesce S, Greppi M, Grossi F, Del Zotto G, Moretta L, Sivori S, et al. PD\/1-PD-Ls checkpoint: insight on the potential role of NK cells. Front Immunol. 2019;10:1242. https:\/\/doi.org\/10.3389\/fimmu.2019.01242.","journal-title":"Front Immunol"},{"issue":"45","key":"2997_CR21","doi-asserted-by":"publisher","first-page":"72961","DOI":"10.18632\/oncotarget.12150","volume":"7","author":"A Beldi-Ferchiou","year":"2016","unstructured":"Beldi-Ferchiou A, Lambert M, Dogniaux S, V\u00e9ly F, Vivier E, Olive D, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget. 2016;7(45):72961\u201377. https:\/\/doi.org\/10.18632\/oncotarget.12150.","journal-title":"Oncotarget"},{"issue":"13","key":"2997_CR22","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"DM Benson","year":"2010","unstructured":"Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286\u201394. https:\/\/doi.org\/10.1182\/blood-2010-02-271874.","journal-title":"Blood"},{"issue":"44","key":"2997_CR23","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/onc.2017.209","volume":"36","author":"Y Liu","year":"2017","unstructured":"Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36(44):6143\u201353. https:\/\/doi.org\/10.1038\/onc.2017.209.","journal-title":"Oncogene"},{"issue":"29","key":"2997_CR24","doi-asserted-by":"publisher","first-page":"12081","DOI":"10.1073\/pnas.0702867104","volume":"104","author":"KR Garrod","year":"2007","unstructured":"Garrod KR, Wei SH, Parker I, Cahalan MD. Natural killer cells actively patrol peripheral lymph nodes forming stable conjugates to eliminate MHC-mismatched targets. Proc Natl Acad Sci. 2007;104(29):12081\u20136. https:\/\/doi.org\/10.1073\/pnas.0702867104.","journal-title":"Proc Natl Acad Sci"},{"issue":"20","key":"2997_CR25","doi-asserted-by":"publisher","first-page":"8437","DOI":"10.1158\/0008-5472.CAN-08-1440","volume":"68","author":"M Wendel","year":"2008","unstructured":"Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 2008;68(20):8437\u201345. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1440.","journal-title":"Cancer Res"},{"issue":"2","key":"2997_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/icb.2010.158","volume":"89","author":"JR Groom","year":"2011","unstructured":"Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89(2):207\u201315. https:\/\/doi.org\/10.1038\/icb.2010.158.","journal-title":"Immunol Cell Biol"},{"issue":"22","key":"2997_CR27","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1158\/1078-0432.CCR-14-0291","volume":"20","author":"E Wennerberg","year":"2014","unstructured":"Wennerberg E, Pfefferle A, Ekblad L, Yoshimoto Y, Kremer V, Kaminskyy VO, et al. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2\/5\/6 and chemoattract NK cells. Clin Cancer Res. 2014;20(22):5733\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0291.","journal-title":"Clin Cancer Res"},{"key":"2997_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","volume":"24","author":"MO Li","year":"2006","unstructured":"Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99\u2013146. https:\/\/doi.org\/10.1146\/annurev.immunol.24.021605.090737.","journal-title":"Annu Rev Immunol"},{"key":"2997_CR29","doi-asserted-by":"publisher","DOI":"10.1101\/648501","author":"K Slattery","year":"2019","unstructured":"Slattery K, Zaiatz-Bittencourt V, Woods E, Brennan K, Marks S, Chew S, et al. TGF\u03b2 drives mitochondrial dysfunction in peripheral blood NK cells during metastatic breast cancer. Biorxiv. 2019. https:\/\/doi.org\/10.1101\/648501.","journal-title":"Biorxiv"},{"issue":"8","key":"2997_CR30","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/eji.200939910","volume":"40","author":"DS Allan","year":"2010","unstructured":"Allan DS, Rybalov B, Awong G, Z\u00fa\u00f1iga-Pfl\u00fccker JC, Kopcow HD, Carlyle JR, et al. TGF-\u03b2 affects development and differentiation of human natural killer cell subsets. Eur J Immunol. 2010;40(8):2289\u201395. https:\/\/doi.org\/10.1002\/eji.200939910.","journal-title":"Eur J Immunol"},{"issue":"8","key":"2997_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/archsurg.136.8.937","volume":"136","author":"SM Sheen-Chen","year":"2001","unstructured":"Sheen-Chen SM, Chen HS, Sheen CW, Eng HL, Chen WJ. Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg. 2001;136(8):937\u201340. https:\/\/doi.org\/10.1001\/archsurg.136.8.937.","journal-title":"Arch Surg"},{"issue":"415","key":"2997_CR32","doi-asserted-by":"publisher","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","volume":"9","author":"S Viel","year":"2016","unstructured":"Viel S, Mar\u00e7ais A, Guimaraes FS, Loftus R, Rabilloud J, Grau M, et al. TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal. 2016;9(415):ra19. https:\/\/doi.org\/10.1126\/scisignal.aad1884.","journal-title":"Sci Signal"},{"issue":"8","key":"2997_CR33","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s10067-017-3711-9","volume":"36","author":"S Mohammadi","year":"2017","unstructured":"Mohammadi S, Ebadpour MR, Sedighi S, Saeedi M, Memarian A. Glucocorticoid-induced leucine zipper expression is associated with response to treatment and immunoregulation in systemic lupus erythematosus. Clin Rheumatol. 2017;36(8):1765\u201372. https:\/\/doi.org\/10.1007\/s10067-017-3711-9.","journal-title":"Clin Rheumatol"},{"key":"2997_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.imlet.2020.10.005","volume":"228","author":"F Ajam","year":"2020","unstructured":"Ajam F, Aghaei M, Mohammadi S, Samiei H, Behnampour N, Memarian A. PD-1 expression on CD8+CD28- T cells within inflammatory synovium is associated with relapse: a cohort of rheumatoid arthritis. Immunol Lett. 2020;228:76\u201382. https:\/\/doi.org\/10.1016\/j.imlet.2020.10.005.","journal-title":"Immunol Lett"},{"issue":"12","key":"2997_CR35","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s00262-004-0556-2","volume":"53","author":"I Caras","year":"2004","unstructured":"Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G, et al. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother. 2004;53(12):1146\u201352. https:\/\/doi.org\/10.1007\/s00262-004-0556-2.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2997_CR36","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.tranon.2016.07.003","volume":"9","author":"NG Nieto-Vel\u00e1zquez","year":"2016","unstructured":"Nieto-Vel\u00e1zquez NG, Torres-Ramos YD, Mu\u00f1oz-S\u00e1nchez JL, Espinosa-Godoy L, G\u00f3mez-Cort\u00e9s S, Moreno J, et al. Altered expression of natural cytotoxicity receptors and NKG2D on peripheral blood NK cell subsets in breast cancer patients. Transl Oncol. 2016;9(5):384\u201391. https:\/\/doi.org\/10.1016\/j.tranon.2016.07.003.","journal-title":"Transl Oncol"},{"issue":"5","key":"2997_CR37","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.4049\/jimmunol.1200140","volume":"190","author":"E Mamessier","year":"2013","unstructured":"Mamessier E, Pradel LC, Thibult ML, Drevet C, Zouine A, Jacquemier J, et al. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol. 2013;190(5):2424\u201336. https:\/\/doi.org\/10.4049\/jimmunol.1200140.","journal-title":"J Immunol"},{"issue":"9","key":"2997_CR38","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1172\/JCI45816","volume":"121","author":"E Mamessier","year":"2011","unstructured":"Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121(9):3609\u201322. https:\/\/doi.org\/10.1172\/JCI45816.","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"2997_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cellimm.2015.09.002","volume":"298","author":"YO Ostapchuk","year":"2015","unstructured":"Ostapchuk YO, Cetin EA, Perfilyeva YV, Yilmaz A, Skiba YA, Chirkin AP, et al. Peripheral blood NK cells expressing HLA-G, IL-10 and TGF-\u03b2 in healthy donors and breast cancer patients. Cell Immunol. 2015;298(1\u20132):37\u201346. https:\/\/doi.org\/10.1016\/j.cellimm.2015.09.002.","journal-title":"Cell Immunol"},{"issue":"5","key":"2997_CR40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4149\/bll_2015_056","volume":"116","author":"M Gharagozloo","year":"2015","unstructured":"Gharagozloo M, Kalantari H, Rezaei A, Maracy MR, Salehi M, Bahador A, et al. The decrease in NKG2D+ natural killer cells in peripheral blood of patients with metastatic colorectal cancer. Bratisl Lek Listy. 2015;116(5):296\u2013301. https:\/\/doi.org\/10.4149\/bll_2015_056.","journal-title":"Bratisl Lek Listy"},{"issue":"11","key":"2997_CR41","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","volume":"7","author":"B Sun","year":"2019","unstructured":"Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res. 2019;7(11):1813\u201323. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0026.","journal-title":"Cancer Immunol Res"},{"key":"2997_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110562","volume":"131","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Li X, Zhang J, Mao L. Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer. Biomed Pharmacother. 2020;131: 110562. https:\/\/doi.org\/10.1016\/j.biopha.2020.110562.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2997_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","volume":"28","author":"N Guerra","year":"2008","unstructured":"Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28(4):571\u201380. https:\/\/doi.org\/10.1016\/j.immuni.2008.02.016.","journal-title":"Immunity"},{"key":"2997_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.713158","volume":"12","author":"MB Fuertes","year":"2021","unstructured":"Fuertes MB, Domaica CI, Zwirner NW. Leveraging NKG2D ligands in immuno-oncology. Front Immunol. 2021;12: 713158. https:\/\/doi.org\/10.3389\/fimmu.2021.713158.","journal-title":"Front Immunol"},{"issue":"1","key":"2997_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10120-011-0059-8","volume":"15","author":"H Saito","year":"2012","unstructured":"Saito H, Osaki T, Ikeguchi M. Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer. Gastric Cancer. 2012;15(1):27\u201333. https:\/\/doi.org\/10.1007\/s10120-011-0059-8.","journal-title":"Gastric Cancer"},{"issue":"4","key":"2997_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.158","volume":"8","author":"J Shen","year":"2017","unstructured":"Shen J, Pan J, Du C, Si W, Yao M, Xu L, et al. Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer. Cell Death Dis. 2017;8(4): e2740. https:\/\/doi.org\/10.1038\/cddis.2017.158.","journal-title":"Cell Death Dis"},{"key":"2997_CR47","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3389\/fimmu.2018.02040","volume":"9","author":"D Schmiedel","year":"2018","unstructured":"Schmiedel D, Mandelboim O. NKG2D ligands-critical targets for cancer immune escape and therapy. Front Immunol. 2018;9:2040. https:\/\/doi.org\/10.3389\/fimmu.2018.02040.","journal-title":"Front Immunol"},{"key":"2997_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2407-12-24","volume":"12","author":"EM de Kruijf","year":"2012","unstructured":"de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA, et al. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer. 2012;12:24. https:\/\/doi.org\/10.1186\/1471-2407-12-24.","journal-title":"BMC Cancer"},{"key":"2997_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081677","author":"R Molfetta","year":"2017","unstructured":"Molfetta R, Quatrini L, Santoni A, Paolini R. Regulation of NKG2D-dependent NK cell functions: the Yin and the Yang of receptor endocytosis. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18081677.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2997_CR50","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","volume":"189","author":"J Hilpert","year":"2012","unstructured":"Hilpert J, Grosse-Hovest L, Gr\u00fcnebach F, Buechele C, Nuebling T, Raum T, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol. 2012;189(3):1360\u201371. https:\/\/doi.org\/10.4049\/jimmunol.1200796.","journal-title":"J Immunol"},{"key":"2997_CR51","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fimmu.2017.00391","volume":"8","author":"A Aquino-L\u00f3pez","year":"2017","unstructured":"Aquino-L\u00f3pez A, Senyukov VV, Vlasic Z, Kleinerman ES, Lee DA. Interferon gamma induces changes in natural killer (NK) cell ligand expression and alters NK cell-mediated lysis of pediatric cancer cell lines. Front Immunol. 2017;8:391. https:\/\/doi.org\/10.3389\/fimmu.2017.00391.","journal-title":"Front Immunol"},{"issue":"2","key":"2997_CR52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1189\/jlb.0611308","volume":"91","author":"R Wang","year":"2012","unstructured":"Wang R, Jaw JJ, Stutzman NC, Zou Z, Sun PD. Natural killer cell-produced IFN-\u03b3 and TNF-\u03b1 induce target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol. 2012;91(2):299\u2013309. https:\/\/doi.org\/10.1189\/jlb.0611308.","journal-title":"J Leukoc Biol"},{"key":"2997_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113285","author":"L Quatrini","year":"2020","unstructured":"Quatrini L, Mariotti FR, Munari E, Tumino N, Vacca P, Moretta L. The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12113285.","journal-title":"Cancers (Basel)"},{"key":"2997_CR54","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3389\/fimmu.2019.00630","volume":"10","author":"R Mizuno","year":"2019","unstructured":"Mizuno R, Sugiura D, Shimizu K, Maruhashi T, Watada M, Okazaki IM, et al. PD-1 primarily targets TCR signal in the inhibition of functional T cell activation. Front Immunol. 2019;10:630. https:\/\/doi.org\/10.3389\/fimmu.2019.00630.","journal-title":"Front Immunol"},{"issue":"31","key":"2997_CR55","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1038\/s41388-021-01896-1","volume":"40","author":"Y Qiu","year":"2021","unstructured":"Qiu Y, Yang Y, Yang R, Liu C, Hsu J-M, Jiang Z, et al. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. Oncogene. 2021;40(31):4992\u20135001. https:\/\/doi.org\/10.1038\/s41388-021-01896-1.","journal-title":"Oncogene"},{"issue":"16","key":"2997_CR56","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","volume":"131","author":"F Vari","year":"2018","unstructured":"Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, et al. Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 2018;131(16):1809\u201319. https:\/\/doi.org\/10.1182\/blood-2017-07-796342.","journal-title":"Blood"},{"issue":"11","key":"2997_CR57","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1172\/JCI74337","volume":"124","author":"M Ardolino","year":"2014","unstructured":"Ardolino M, Azimi CS, Iannello A, Trevino TN, Horan L, Zhang L, et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest. 2014;124(11):4781\u201394. https:\/\/doi.org\/10.1172\/JCI74337.","journal-title":"J Clin Invest"},{"key":"2997_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002044","author":"K Slattery","year":"2021","unstructured":"Slattery K, Woods E, Zaiatz-Bittencourt V, Marks S, Chew S, Conroy M, et al. TGF\u03b2 drives NK cell metabolic dysfunction in human metastatic breast cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-002044.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2997_CR59","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.4049\/jimmunol.1701461","volume":"200","author":"V Zaiatz-Bittencourt","year":"2018","unstructured":"Zaiatz-Bittencourt V, Finlay DK, Gardiner CM. Canonical TGF-\u03b2 signaling pathway represses human NK cell metabolism. J Immunol. 2018;200(12):3934\u201341. https:\/\/doi.org\/10.4049\/jimmunol.1701461.","journal-title":"J Immunol"},{"issue":"1","key":"2997_CR60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1517\/13543780903382609","volume":"19","author":"NS Nagaraj","year":"2010","unstructured":"Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs. 2010;19(1):77\u201391. https:\/\/doi.org\/10.1517\/13543780903382609.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"2997_CR61","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1073\/pnas.0730640100","volume":"100","author":"R Castriconi","year":"2003","unstructured":"Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A. 2003;100(7):4120\u20135. https:\/\/doi.org\/10.1073\/pnas.0730640100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2997_CR62","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.immuni.2006.03.016","volume":"24","author":"J Yu","year":"2006","unstructured":"Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, et al. Pro-and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity. 2006;24(5):575\u201390. https:\/\/doi.org\/10.1016\/j.immuni.2006.03.016.","journal-title":"Immunity"},{"issue":"10","key":"2997_CR63","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MC Cheang","year":"2009","unstructured":"Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736\u201350. https:\/\/doi.org\/10.1093\/jnci\/djp082.","journal-title":"J Natl Cancer Inst"},{"key":"2997_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fimmu.2020.00311","volume":"11","author":"S Regis","year":"2020","unstructured":"Regis S, Dondero A, Caliendo F, Bottino C, Castriconi R. NK cell function regulation by TGF-\u03b2-induced epigenetic mechanisms. Front Immunol. 2020;11:311. https:\/\/doi.org\/10.3389\/fimmu.2020.00311.","journal-title":"Front Immunol"},{"issue":"1","key":"2997_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1238","volume":"10","author":"L Riggan","year":"2021","unstructured":"Riggan L, Shah S, O\u2019Sullivan TE. Arrested development: suppression of NK cell function in the tumor microenvironment. Clin Transl Immunology. 2021;10(1): e1238. https:\/\/doi.org\/10.1002\/cti2.1238.","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"2997_CR66","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s40425-019-0751-5","volume":"7","author":"V Bonanni","year":"2019","unstructured":"Bonanni V, Antonangeli F, Santoni A, Bernardini G. Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells. J Immunother Cancer. 2019;7(1):290. https:\/\/doi.org\/10.1186\/s40425-019-0751-5.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2997_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100930","volume":"14","author":"S Nersesian","year":"2021","unstructured":"Nersesian S, Schwartz SL, Grantham SR, MacLean LK, Lee SN, Pugh-Toole M, et al. NK cell infiltration is associated with improved overall survival in solid cancers: a systematic review and meta-analysis. Transl Oncol. 2021;14(1): 100930. https:\/\/doi.org\/10.1016\/j.tranon.2020.100930.","journal-title":"Transl Oncol"},{"key":"2997_CR68","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3389\/fimmu.2020.01242","volume":"11","author":"S Zhang","year":"2020","unstructured":"Zhang S, Liu W, Hu B, Wang P, Lv X, Chen S, et al. Prognostic significance of tumor-infiltrating natural killer cells in solid tumors: a systematic review and meta-analysis. Front Immunol. 2020;11:1242. https:\/\/doi.org\/10.3389\/fimmu.2020.01242.","journal-title":"Front Immunol"},{"issue":"11","key":"2997_CR69","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.4049\/jimmunol.181.11.7985","volume":"181","author":"TR Wuest","year":"2008","unstructured":"Wuest TR, Carr DJ. Dysregulation of CXCR3 signaling due to CXCL10 deficiency impairs the antiviral response to herpes simplex virus 1 infection. J Immunol. 2008;181(11):7985\u201393. https:\/\/doi.org\/10.4049\/jimmunol.181.11.7985.","journal-title":"J Immunol"},{"issue":"1","key":"2997_CR70","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10549-011-1944-x","volume":"134","author":"K Kajitani","year":"2012","unstructured":"Kajitani K, Tanaka Y, Arihiro K, Kataoka T, Ohdan H. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells. Breast Cancer Res Treat. 2012;134(1):139\u201355. https:\/\/doi.org\/10.1007\/s10549-011-1944-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2997_CR71","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.yexmp.2015.06.002","volume":"99","author":"AA Ejaeidi","year":"2015","unstructured":"Ejaeidi AA, Craft BS, Puneky LV, Lewis RE, Cruse JM. Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis. Exp Mol Pathol. 2015;99(1):163\u201372. https:\/\/doi.org\/10.1016\/j.yexmp.2015.06.002.","journal-title":"Exp Mol Pathol"},{"issue":"5","key":"2997_CR72","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/CJI.0b013e318031b551","volume":"30","author":"TC Walser","year":"2007","unstructured":"Walser TC, Ma X, Kundu N, Dorsey R, Goloubeva O, Fulton AM. Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J Immunother. 2007;30(5):490\u20138. https:\/\/doi.org\/10.1097\/CJI.0b013e318031b551.","journal-title":"J Immunother"},{"issue":"3","key":"2997_CR73","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.4049\/jimmunol.175.3.1636","volume":"175","author":"OM Hart","year":"2005","unstructured":"Hart OM, Athie-Morales V, O\u2019Connor GM, Gardiner CM. TLR7\/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol. 2005;175(3):1636\u201342. https:\/\/doi.org\/10.4049\/jimmunol.175.3.1636.","journal-title":"J Immunol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02997-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-022-02997-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02997-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T14:34:03Z","timestamp":1676990043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-022-02997-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":73,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["2997"],"URL":"https:\/\/doi.org\/10.1007\/s12094-022-02997-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of Golestan University of Medical Sciences (No: IR.GOUMS.REC.1398.020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent following the Declaration of Helsinki was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}